Seminars in Hematology
Volume 42, Issue 4 , Pages 248-258 , October 2005

Idiopathic Myelofibrosis

  • Giovanni Barosi

      Affiliations

    • Laboratory of Clinical Epidemiology, IRCCS Policlinico S. Matteo, Pavia, Italy.
    • ,
  • Ronald Hoffman

      Affiliations

    • University of Illinois College of Medicine, Chicago, IL.
    • Corresponding Author InformationAddress correspondence to Ronald Hoffman, MD, Eileen Heidrick Professor of Oncology, University of Illinois Cancer Center, University of Illinois College of Medicine, 900 S Ashland Ave, Room 1058 MBRB, MC 700, Chicago, IL 60607.

References 

  1. Tefferi A . Myelofibrosis with myeloid metaplasia . N Engl J Med . 2000;342:1255–1265
  2. Pettit JE , Lewis SM , Nicholas AW . Transitional myeloproliferative disorder . Br J Haematol . 1979;43:167–184
  3. Thiele J , Kvasnicka HM , Boeltken B , Zankovich R , Diehl V , Fischer R . Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)—A clinicopathological study . Leukemia . 1999;13:1741–1748
  4. Thiele J , Kvasnicka HM , Schmitt-Graeff A , Diehl V . Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy (A follow-up study on 309 patients) . Leuk Lymphoma . 2003;44:949–953
  5. Buhr T , Busche G , Choritz H , Langer F , Kreipe H . Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens . Am J Clin Pathol . 2003;119:152–158
  6. Thiele J , Pierre R , Imbert M , Vardiman JW , Brunning RD , Flandrin G . Chronic idiopathic myelofibrosis . In:  Jaffe ES ,  Harris NL ,  Stein H , et al. editor. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues . Lyon, France: IARC Press; 2001;p. 35–38
  7. Polino G , Barosi G , Berzuini A , Castelli G , Isernia P , Palestra P , et al.   Fatty bone marrow with severe myeloid hypoplasia in idiopathic myelofibrosis . Haematologica . 1986;71:117–121
  8. Gerli GC , Gianelli U , Carraro MC , Bestetti A , Marchetti M , Barosi G . Myelofibrosis with myeloid metaplasia with fatty bone marrow (Report of a new case) . Haematologica . 2001;86:885–886
  9. Rudzki Z , Sacha T , Okon K , Skotnicki AB . Idiopathic myelofibrosis with fatty bone marrow (An issue of sampling? A propos an unusual case) . Haematologica . 2003;88:ELT05
  10. Horikawa Y , Matsumura I , Hashimoto K , Shiraga M , Kosugi S , Tadokoro S , et al.   Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia . Blood . 1997;90:4031–4038
  11. Moliterno AR , Hankins WD , Spivak JL . Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera . N Engl J Med . 1998;338:572–580
  12. Kralovics R , Skoda RC . Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders . Blood Rev . 2005;19:1–13
  13. Temerinac S , Klippel S , Strunck E , et al.   Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera . Blood . 2000;95:2569–2576
  14. Tefferi A , Lasho TL , Wolanskyj AP , Mesa RA . Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia . Blood . 2004;103:3547–3548
  15. Passamonti F , Pietra D , Malabarba L , Rumi E , Della Porta MG , Malcovati L , et al.   Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders . Br J Haematol . 2004;126:650–656
  16. Kralovics R , Buser AS , Teo SS , Coers J , Tichelli A , van der Maas AP , et al.   Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders . Blood . 2003;102:1869–1871
  17. Barosi G , Viarengo G , Pecci A , Rosti V , Piaggio G , Marchetti M , et al.   Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia . Blood . 2001;98:3249–3255
  18. Andreasson B , Swolin B , Kutti J . Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia . Eur J Haematol . 2002;68:189–193
  19. Passamonti F , Vanelli L , Malabarba L , Rumi E , Pungolino E , Malcovati L , et al.   Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders . Haematologica . 2003;88:1123–1129
  20. Arora B , Sirhan S , Hoyer JD , Mesa RA , Tefferi A . Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia (A prospective evaluation of prognostic value in 94 patients) . Br J Haematol . 2005;128:42–48
  21. Rafii S , Lyden D . Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration . Nature Med . 2003;9:702–712
  22. Massa M , Rosti V , Ferrario M , Campanelli R , Ramajoli I , Rosso R , et al.   Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction . Blood . 2004;105:199–206
  23. Zhang H , Vakil V , Braunstein M , Smith EL , Maroney J , Chen L , et al.   Circulating endothelial progenitor cells in multiple myeloma (Implications and significance) . Blood . 2005;105:3286–3294
  24. Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G, et al: Circulating CD34+CD133+VEGFR-2+ endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol (in press)
  25. Jacobson RJ , Salo A , Fialkow PJ . Agnogenic myeloid metaplasia (A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis) . Blood . 1978;51:189–194
  26. Lucas GS , Padua RA , Masters GS , Oscier DG , Jacobs A . The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease . Br J Haematol . 1989;72:530–533
  27. Greenberg BR , Woo L , Veomett IC , Payne CM , Ahmann FR . Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis . Br J Haematol . 1987;66:487–490
  28. Xu M , Bruno E , Chao J , Ni H , Lindgren V , Nunez R , et al.   The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis . Blood . 2005;105:1699–1705
  29. Devine SM , Hoffman R , Verma A , Shah R , Bradlow BA , Stock W , et al.   Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia . Blood . 2002;99:2255–2258
  30. Emadi S , Clay D , Desterke C , Guerton B , Maquarre E , Charpentier A , et al.   IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis . Blood . 2005;105:464–473
  31. Martyré MC , Romquin N , Le Bousse-Kerdiles MC , Chevillard S , Benyahia B , Dupriez B , et al.   Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis . Br J Haematol . 1994;88:9–16
  32. Martyré MC . TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders . Leuk Lymphoma . 1995;1-2:39–44
  33. Martyré MC , Magdelenat H , Bryckaert MC , Laine-Bidron C , Calvo F . Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia . Br J Haematol . 1991;1:80–86
  34. Le Bousse-Kerdiles MC , Martyré MC . Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis . Ann Hematol . 1999;78:437–444
  35. Nakamura T , Okuda S , Miller D , et al.   Transforming growth factor-β (TGF-β) regulates production of extracellular matrix (ECM) components by glomerular epithelial cells . Kidney Int . 1990;37:221–226
  36. Varga J , Rosenbloom J , Jimenez SA . Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts . Biochem J . 1987;247:597–604
  37. Overall CM , Wrana JL , Sodek J . Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta . J Biol Chem . 1989;264:186–189
  38. Martyré MC , Le Bousse-Kerdiles MC , Romquin N , Chevillard S , Praloran V , Demory JL , et al.   Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis . Br J Haematol . 1997;97:441–448
  39. Klagsbrun M . The fibroblast growth factor family (Structural and biological properties) . Prog Growth Factor Res . 1989;1:207–235
  40. Musolino C , Calabro L , Bellomo G , et al.   Soluble angiogenic factors (Implications for chronic myeloproliferative disorders) . Am J Hematol . 2002;69:159–163
  41. Yan XQ , Lacey D , Fletcher F , Hartley C , McElroy P , Sun Y , et al.   Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice . Blood . 1995;86:4025–4033
  42. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand) (Reversal of disease by bone marrow transplantation) . Blood . 1996;88:402–409
  43. Zhou W , Toombs CF , Zou T , Guo J , Robinson MO . Transgenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment . Blood . 1997;89:1551–1559
  44. Vannucchi AM , Bianchi L , Cellai C , Paoletti F , Rana RA , Lorenzini R , et al.   Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice) . Blood . 2002;100:1123–1132
  45. Schmitt A , Jouault H , Guichard J , Wendling F , Drouin A , Cramer EM . Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis . Blood . 2000;96:1342–1347
  46. Centurione L , Di Baldassarre A , Zingariello M , Bosco D , Gatta V , Rana RA , et al.   Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice . Blood . 2004;104:3573–3580
  47. Rameshwar P , Denny TN , Stein D , Gascon P . Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta . J Immunol . 1994;153:2819–2830
  48. Rameshwar P , Narayanan R , Qian J , Denny TN , Colon C , Gascon P . NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis (An inflammatory response beyond the realm of homeostasis) . J Immunol . 2000;165:2271–2277
  49. Frey BM , Rafii S , Teterson M , Eaton D , Crystal RG , Moore MA . Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice (Insights into the pathophysiology of osteomyelofibrosis) . J Immunol . 1998;160:691–699
  50. Thiele J , Rompcik V , Wagner S , Fischer R . Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera (An immunomorphometric study on trephine biopsies of the bone marrow) . Br J Haematol . 1992;8:227–234
  51. Charbord P . Increased vascularity of bone marrow in myelofibrosis . Br J Haematol . 1986;62:595–596
  52. Lundberg LG , Lerner R , Sundelin P , Rogers R , Folkman J , Palmblad J . Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity . Am J Pathol . 2000;157:15–19
  53. Mesa RA , Hanson CA , Rajkumar SV , Schroeder G , Tefferi A . Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia . Blood . 2000;96:3374–3380
  54. Vannucchi AM , Bianchi L , Paoletti F , Pancrazzi A , Torre E , Nishikawa M , et al.   A patho-biological pathway linking thrombopoietin, GATA-1 and TGF-beta1 in the development of myelofibrosis . Blood . 2005;105:3493–3501
  55. Di Raimondo F , Azzaro MP , Palumbo GA , Bagnato S , Stagno F , Giustolisi GM , et al.   Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis . Leukemia . 2001;15:976–980
  56. Bergamaschi G , Pramparo T , Rosti V , Ramajoli I , Gregato G , Massa M , et al.   Clonal origin of circulating endothelial progenitor cells in patients with myelofibrosis with myeloid metaplasia . Blood . 2004;104:667a; (abstr)
  57. Pelosi E , Valtieri M , Coppola S , Botta R , Gabbianelli M , Lulli V , et al.   Identification of the hemangioblast in postnatal life . Blood . 2002;100:3203–3208
  58. Ditschkowski M , Beelen DW , Trenschel R , Koldehoff M , Elmaagacli AH . Outcome of allogeneic stem cell transplantation in patients with myelofibrosis . Bone Marrow Transplant . 2004;34:807–813
  59. Rondelli D , Barosi G , Bacigalupo A , Prchal JT , Popat U , Alessandrino EP , et al.   Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia . Blood . 2005;105:4115–4119
  60. Kroger N , Zabelina T , Schieder H , Panse J , Ayuk F , Stute N , et al.   Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis . Br J Haematol . 2005;128:690–697
  61. Anderson JE , Tefferi A , Craig F , Holmberg L , Chauncey T , Appelbaum FR , et al.   Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis . Blood . 2001;98:586–593
  62. Xu M , Bruno E , Chao J , Huang S , Finazzi G , Fruchtman SM , et al.   The constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases . Blood . 2005;105:3714–3721
  63. Janowska-Wieczorek A , Marquez LA , Nabholtz JM , Cabuhat ML , Montano J , Chang H , et al.   Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane . Blood . 1999;93:3379–3390
  64. Martyré MC , Steunou V , Le Bousse-Kerdiles MC , Wietzerbin J . Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis . Blood . 2003;101:5087–5088
  65. Jones LC , Tefferi A , Idos GE , Kumagai T , Hofmann WK , Koeffler HP . RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia . Oncogene . 2004;23:7846–7853
  66. Fisher C , Steensma D , Janmohamed R , Kaczmarski R , Reilly JT , Vyas P . Absence of mutations in the key megakaryocyte transcriptional regulator FOG-1 in patients with idiopathic myelofibrosis . Br J Haematol . 2004;126:750–752
  67. Al-Assar O , Ul-Hassan A , Brown R , Wilson GA , Hammond DW , Reilly JT . Gains on 9p are common genomic aberrations in idiopathic myelofibrosis (A comparative genomic hybridization study) . Br J Haematol . 2005;129:66–71
  68. Gurbuxani S , Vyas P , Crispino JD . Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome . Blood . 2004;103:399–406
  69. James C , Ugo V , Le Couedic JP , Staerk J , Delhommeau F , Lacout C , et al.   A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera . Nature . 2005;434:1144–1148
  70. Baxter EJ , Scott LM , Campbell PJ , East C , Fourouclas N , Swanton S , et al.   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders . Lancet . 2005;365:1054–1061
  71. Kralovics R , Passamonti F , Buser AS , Teo S-S , Tiedt R , Passweg JR , et al.   A gain-of-function mutation of JAK2 in Myeloproliferative Disorders . N Engl J Med . 2005;352:1779–1790
  72. Levine RL , Wadleigh M , Cools J , Ebert BL , Wernig G , Hutnly BJP , et al.   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis . Cancer Cell . 2005;7:387–397
  73. Odero MD , Grand FH , Iqbal S , Ross F , Roman JP , Vizmanos JL , et al.   Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies . Leukemia . 2005;19:245–252
  74. Kumagai T , Tefferi A , Jones L , Koeffler HP . Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia . Leuk Res . 2005;29:511–515
  75. Vannucchi AM, Pancrazzi, Bianchi L, Guglielmelli P, Di Lollo S, Bogani C, et al: Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Clin Pathol (in press)
  76. Barosi G , Berzuini C , Liberato LN , Costa A , Polino G , Ascari E . A prognostic classification of myelofibrosis with myeloid metaplasia . Br J Haematol . 1988;70:397–401
  77. Visani G , Finelli C , Castelli U , Petti MC , Ricci P , Vianelli N , et al.   Myelofibrosis with myeloid metaplasia (Clinical and haematological parameters predicting survival in a series of 133 patients) . Br J Haematol . 1990;75:4–9
  78. Rupoli S , Da Lio L , Sisti  , Campanati G , Salvi A , Brianzoni MF , et al.   Primary myelofibrosis (A detailed statistical analysis of the clinicopathological variables influencing survival) . Ann Hematol . 1994;68:205–212
  79. Cervantes F , Pereira A , Esteve J , Rafel M , Cobo F , Rozman C , et al.   Identification of “short-lived” and “long-lived” patients at presentation of idiopathic myelofibrosis . Br J Haematol . 1997;97:635–640
  80. Reilly JT , Snowden JA , Spearing RL , Fitzgerald PM , Jones N , Watmore A , et al.   Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis (A study of 106 cases) . Br J Haematol . 1997;98:96–102
  81. Kvasnicka HM , Thiele J , Werden C , Zankovich R , Diehl V , Fischer R . Prognostic factors in idiopathic (primary) osteomyelofibrosis . Cancer . 1997;80:708–719
  82. Tefferi A , Mesa RA , Schroeder G , Hanson CA , Li Ch-Y , Dewald GW . Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia . Br J Haematol . 2001;113:763–771
  83. Okamura T , Kinukawa N , Niho Y , Mizoguchi H . Primary chronic myelofibrosis (Clinical and prognostic evaluation in 336 Japanese patients) . Int J Hematol . 2001;73:194–198
  84. Dupriez B , Morel P , Demory JL , Lai JL , Simon M , Plantier I , et al.   Prognostic factors in agnogenic myeloid metaplasia (A report on 195 cases with a new scoring system) . Blood . 1996;88:1013–1018
  85. Varki A , Lottenberg R , Griffith R , Reinhard E . The syndrome of idiopathic myelofibrosis (A clinicopathologic review with emphasis on the prognostic variables predicting survival) . Medicine (Baltimore) . 1983;62:353–371
  86. Njoku OS , Lewis SM , Catovsky D , Gordon-Smith EC . Anaemia in myelofibrosis (Its value in prognosis) . Br J Haematol . 1983;54:78–89
  87. Cervantes F , Barosi G , Demory JL , Reilly J , Guarnone R , Dupriez B , et al.   Myelofibrosis with myeloid metaplasia in young individuals (Disease characteristics, prognostic factors and identification of risk groups) . Br J Haematol . 1998;102:684–690
  88. Hast R , Engstedt L , Jameson S , Killander A , Lundh B , Reizenstein P , et al.   Oxymetolone treatment in myelofibrosis . Blut . 1978;37:19–26
  89. Cervantes F , Hernandez-Boluda JC , Alvarez A , Nadal E , Montserrat E . Danazol treatment of idiopathic myelofibrosis with severe anemia . Haematologica . 2000;85:595–599
  90. Cervantes F , Alvarez-Larran A , Hernandez-Boluda JC , Sureda A , Torrebadell M , Montserrat E . Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia (Results in 20 patients and review of the literature) . Br J Haematol . 2004;127:399–403
  91. Barosi G , Elliott M , Canepa L , Ballerini F , Piccaluga PP , Visani G , et al.   Thalidomide in myelofibrosis with myeloid metaplasia (A pooled-analysis of individual patient data from 5 studies) . Leuk Lymph . 2002;43:2301–2307
  92. Marchetti M , Barosi G , Balestri F , Viarengo G , Gentili S , Barulli S , et al.   Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia (A phase II trial) . J Clin Oncol . 2004;22:231
  93. Mesa RA , Steensma DP , Pardanani A , Li CY , Elliott M , Kaufmann SH , et al.   A phase II trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia . Blood . 2003;101:2534–2541
  94. Mesa RA , Elliott MA , Schroeder G , Tefferi A . Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia . Mayo Clin Proc . 2004;79:883–889
  95. Manoharan A . Management of myelofibrosis with intermittent hydroxyurea . Br J Haematol . 1991;77:252–254
  96. Lofvenberg E , Wahlin A , Ross G , Ost A . Reversal of myelofibrosis by hydroxyurea . Eur J Haematol . 1990;44:33–38
  97. Petti MC , Latagliata R , Spadea T , Spadea A , Montefusco E , Aloe Spiriti MA , et al.   Melphalan treatment in patients with myelofibrosis with myeloid metaplasia . Br J Haematol . 2002;116:576–581
  98. Barosi G , Liberato NL , Costa A , Ascari E . Cytoreductive effect of recombinant alfa-interferon in patients with myelofibrosis with myeloid metaplasia . Haematologica . 1990;75(suppl 4):48–50
  99. Gilbert HS . Long-term treatment of myeloproliferative disease with interferon-alpha-2b (Feasibility and efficacy) . Cancer . 1998;83:1205–1213
  100. Tefferi A , Mesa RA , Gray LA , Steensma DP , Camoriano JK , Elliott MA , et al.   Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia . Blood . 2002;99:3854–3856
  101. Hasselbalch HC , Bjerrum OW , Jensen BA , Clausen NT , Hansen PB , Birgens H , et al.   Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis . Am J Hematol . 2003;74:238–242
  102. Guardiola P , Anderson JE , Bandini G , Cervantes F , Runde V , Arcese W , et al.   Allogeneic stem cell transplantation for agnogenic myeloid metaplasia (A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study) . Blood . 1999;93:2831–2838
  103. Daly A , Song K , Nevill T , Nantel S , Toze C , Hogge D , et al.   Stem cell transplantation for myelofibrosis (A report from two Canadian centers) . Bone Marrow Transplant . 2003;32:35–40
  104. Deeg HJ , Gooley TA , Flowers ME , Sale GE , Slattery JT , Anasetti C , et al.   Allogeneic hematopoietic stem cell transplantation for myelofibrosis . Blood . 2003;102:3912–3918

 Supported by funds from the MPD Research Foundation and the US Department of Defense.

PII: S0037-1963(05)00078-8

doi: 10.1053/j.seminhematol.2005.05.018

Seminars in Hematology
Volume 42, Issue 4 , Pages 248-258 , October 2005

Article Tools